Last, TMB seemed to be a more valuable biomarker for the efficacy of ICBs in SCLC, and the combination of TMB and PD-L1 may be promising for selecting patients who benefit from immunotherapy in SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.